Two-Year Outcomes of Anticoagulation for Acute Ischemic Stroke With Nonvalvular Atrial Fibrillation - SAMURAI-NVAF Study -

被引：37

作者：

Yoshimura, Sohei ^{[1
,8
,9
]}

Koga, Masatoshi ^{[1
]}

Sato, Shoichiro ^{[1
]}

Todo, Kenichi ^{[3
]}

Yamagami, Hiroshi ^{[2
]}

Kumamoto, Masaya ^{[1
]}

Itabashi, Ryo ^{[4
]}

Terasaki, Tadashi ^{[5
]}

Kimura, Kazumi ^{[6
]}

Yagita, Yoshiki ^{[7
]}

Shiokawa, Yoshiaki

Kamiyama, Kenji ^{[10
]}

Okuda, Satoshi ^{[11
]}

Okada, Yasushi ^{[12
]}

Takizawa, Shunya ^{[13
]}

Hasegawa, Yasuhiro ^{[14
]}

Kameda, Tomoaki ^{[15
]}

Shibuya, Satoshi ^{[16
]}

Nagakane, Yoshinari ^{[17
]}

Ito, Yasuhiro ^{[18
]}

Matsuoka, Hideki ^{[19
]}

Takamatsu, Kazuhiro ^{[20
]}

Nishiyama, Kazutoshi ^{[21
]}

Fujita, Kyohei ^{[1
]}

Kamimura, Teppei ^{[2
]}

Ando, Daisuke ^{[1
]}

Ide, Toshihiro ^{[1
]}

Yoshimoto, Takeshi ^{[2
]}

Shiozawa, Masayuki ^{[1
]}

Matsubara, Soichiro ^{[1
]}

Yamaguchi, Yoshitaka ^{[1
]}

Kinoshita, Naoto ^{[2
]}

Matsuki, Takayuki ^{[1
]}

Takasugi, Junji ^{[2
]}

Tokunaga, Keisuke ^{[1
]}

Higashida, Kyoko ^{[2
]}

Homma, Kazunari ^{[13
]}

Kario, Kazuomi ^{[15
]}

Arihiro, Shoji ^{[1
]}

Toyoda, Kazunori ^{[1
]}

机构：

[1] Natl Cerebral & Cardiovasc Ctr, Dept Cerebrovasc Med, 5-7-1 Fujishirodai, Suita, Osaka 5658565, Japan

[2] Natl Cerebral & Cardiovasc Ctr, Dept Neurol, Suita, Osaka, Japan

[3] Kobe City Med Ctr Gen Hosp, Dept Neurol, Kobe, Hyogo, Japan

[4] Kohnan Hosp, Dept Stroke Neurol, Sendai, Miyagi, Japan

[5] Japanese Red Cross Kumamoto Hosp, Dept Neurol, Kumamoto, Japan

[6] Nippon Med Coll Hosp, Grad Sch Med, Dept Neurol Sci, Tokyo, Japan

[7] Kawasaki Med Sch, Dept Stroke Med, Kurashiki, Okayama, Japan

[8] Kyorin Univ, Dept Neurosurg, Sch Med, Mitaka, Tokyo, Japan

[9] Kyorin Univ, Stroke Ctr, Sch Med, Mitaka, Tokyo, Japan

[10] Nakamura Mem Hosp, Dept Neurosurg, Sapporo, Hokkaido, Japan

[11] NHO Nagoya Med Ctr, Dept Neurol, Nagoya, Aichi, Japan

[12] NHO Kyushu Med Ctr, Dept Neurol & Cerebrovasc Med, Fukuoka, Japan

[13] Tokai Univ, Dept Neurol, Sch Med, Isehara, Kanagawa, Japan

[14] St Marianna Univ, Dept Neurol, Sch Med, Kawasaki, Kanagawa, Japan

[15] Jichi Med Univ, Sch Med, Div Neurol, Shimotsuke, Japan

[16] South Miyagi Med Ctr, Dept Neurol, Ogawara, Japan

[17] Kyoto Second Red Cross Hosp, Dept Neurol, Kyoto, Japan

[18] TOYOTA Mem Hosp, Dept Neurol, Toyota, Japan

[19] NHO Kagoshima Med Ctr, Dept Cerebrovasc Med, Kagoshima, Japan

[20] Ohta Mem Hosp, Dept Neurol, Fukuyama, Hiroshima, Japan

[21] Kitasato Univ, Sch Med, Dept Neurol, Sagamihara, Kanagawa, Japan

来源：

CIRCULATION JOURNAL | 2018年 / 82卷 / 07期

关键词：

Acute stroke; Atrial fibrillation; Direct oral anticoagulants; Intracranial hemorrhage; Warfarin; JAPANESE PATIENTS; WARFARIN; RISK; DABIGATRAN; METAANALYSIS; MORTALITY;

D O I：

10.1253/circj.CJ-18-0067

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Background: We determined the 2-year long-term risk-benefit profile in patients with stroke or transient ischemic attack (TIA) receiving warfarin or direct oral anticoagulants (DOACs) for nonvalvular atrial fibrillation (NVAF) using a prospective, multicenter, observational registry in Japan. Methods and Results: NVAF patients within 7 days after onset of ischemic stroke/TIA were enrolled in 18 stroke centers. Outcome measures included ischemic and bleeding events and death in the 2-year follow-up period. We enrolled 1,116 patients taking either warfarin (650 patients) or DOACs (466 patients) at acute hospital discharge. DOAC users were younger and had lower National Institutes of Health Stroke Scale, CHADS(2) and discharge modified Rankin Scale scores than warfarin users (P<0.0001 each). Incidences of stroke/systemic embolism (adjusted hazard ratio, 1.07; 95% CI, 0.66-1.72), all ischemic events (1.13; 0.72-1.75), and ischemic stroke/TIA (1.58; 0.95-2.62) were similar between groups. Risks of intracranial hemorrhage (0.32; 0.09-0.97) and death (0.41; 0.26-0.63) were significantly lower for DOAC users. Infection was the leading cause of death, accounting for 40% of deaths among warfarin users. Conclusions: Stroke/TIA patients receiving DOACs for secondary prevention were younger and had lower stroke severity and risk indices than those receiving warfarin. Estimated cumulative incidences of stroke and systemic embolism within 2 years were similar between warfarin and DOACs users, but those of death and intracranial hemorrhage were significantly lower among DOAC users.

引用

页码：1935 / +

页数：10

共 50 条

[41] Outcomes of early anticoagulation following ischemic stroke or transient ischemic attack in the setting of atrial fibrillation
Smith, D. B.
Stotts, G.
Beliavsky, A.
Dowlatshahi, D.
CEREBROVASCULAR DISEASES, 2013, 35 : 742 - 743
[42] Outcomes and Antithrombotic Regimens in Nonvalvular Atrial Fibrillation Patients With Acute Ischemic Stroke and Competing Large-Artery Atherosclerosis
Xue, Sufang
Na, Risu
Dong, Jing
Qiu, Xue
Wei, Min
Kong, Qi
Wang, Qiujia
Li, Fangyu
Wang, Yan
NEUROLOGIST, 2025, 30 (02) : 102 - 108
[43] Clinical outcomes of anticoagulation for stroke prevention in atrial fibrillation: A 10 year cohort study.
Weibert, RT
Jackson, C
Feld, GK
STROKE, 2001, 32 (01) : 377 - 377
[44] Left Atrial Enlargement is Associated With Anticoagulation Failure in Patients With Acute Ischemic Stroke and Atrial Fibrillation
Dakay, Katarina
Chang, Andrew D.
Hemendinger, Morgan
Cutting, Shawna M.
McTaggart, Ryan A.
Jayaraman, Mahesh V.
Chu, Antony
Panda, Nikhil
Song, Christopher
Merkler, Alexander
Gialdini, Gino
Kummer, Benjamin
Lerario, Michael P.
Kamel, Hooman
Elkind, Mitchell S.
Furie, Karen L.
Yaghi, Shadi
STROKE, 2018, 49
[45] Effects of Anticoagulation on Low-Density Lipoprotein-Cholesterol and Ischemic Stroke in Patients with Nonvalvular Atrial Fibrillation
Ismail, Zeeshan H.
Asnake, Zekarias T.
Salabei, Joshua K.
AMERICAN JOURNAL OF MEDICINE, 2021, 134 (10):
[46] Use of Warfarin at Discharge Among Acute Ischemic Stroke Patients With Nonvalvular Atrial Fibrillation in China
Yang, Xiaomeng
Li, Zixiao
Zhao, Xingquan
Wang, Chunjuan
Liu, Liping
Wang, Chunxue
Pan, Yuesong
Li, Hao
Wang, David
Hart, Robert G.
Wang, Yilong
Wang, Yongjun
STROKE, 2016, 47 (02) : 464 - 470
[47] A two-year follow-up of ximelagatran as an oral anticoagulant for the prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation
Petersen, P
NEUROLOGY, 2002, 58 (07) : A477 - A477
[48] Timing of Treatment Initiation With Oral Anticoagulants for Acute Ischemic Stroke in Patients With Nonvalvular Atrial Fibrillation
Deguchi, Ichiro
Tanahashi, Norio
Takao, Masaki
CIRCULATION JOURNAL, 2017, 81 (02) : 180 - 184
[49] What Is the Best Anticoagulant Therapy in Acute-Phase Ischemic Stroke With Nonvalvular Atrial Fibrillation?
Fujimoto, Shigeru
CIRCULATION JOURNAL, 2022, 86 (06) : 964 - 965
[50] Early vs late anticoagulation in acute ischemic stroke with indications outside atrial fibrillation
Jumah, Ammar
Fu, Siyuan
Albanna, Abdalla Jamal
Agarwal, Utkarsh
Fana, Michael
Choudhury, Omar
Idris, Anas
Elfaham, Abdelrahman
Iqbal, Zahid
Schultz, Lonni
Latack, Katie
Brady, Megan
Scozzari, Dawn
Ramadan, Ahmad Riad
JOURNAL OF STROKE & CEREBROVASCULAR DISEASES, 2024, 33 (07):

← 1 2 3 4 5 →